Jeffrey Hafkin

Pharmaceutical Product Development (United States)

Also affiliated with Otsuka (United States), Otsuka Pharmaceutical (Spain)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial”.

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial

Kidney International Reports(2025)10.1016/j.ekir.2025.09.031

N/A

0.241DataRank · unranked

4 citations

Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll +11 more

Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.108084

N/A

0DataRank · unranked

0 citations

Michael D. Hughes, Soyeon Kim, Lisa Aaron, Linda Naini, Nishi Suryavanshi +14 more